Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates

• DOI: 10.1016/j.vaccine.2020.03.008
• Publication Date: 2020-03-14T12:34:27Z
• Authors: Appavu K. Sundaram; Daniel Ewing; Maria Blevins; Zhaodong Liang; Sandy Sink; Josef Lassan; Kanakatte Ravipra...; Gabriel Defang; Maya Williams; Kevin R. Porter; John W. Sanders
• Keywords: Dengue vaccine

Dengue fever, caused by dengue viruses (DENV 1-4) is a leading cause of illness and death in the tropics subtropics. Therefore, an effective vaccine urgently needed. Currently, only available licensed chimeric live attenuated that shows varying efficacy depending on serotype, age baseline DENV serostatus. Accordingly, seronegative adults, children all ages immunocompromised individuals still We are currently researching use psoralen to develop inactivated tetravalent vaccine. Unlike traditional formalin inactivation, inactivates pathogens at nucleic acid level, potentially preserving envelope protein epitopes important for protective anti-dengue immune responses. prepared highly purified monovalent lots formalin- psoralen-inactivated 1-4, using Capto DeVirS Core 700 resin based column chromatography. Tetravalent vaccines (PsIV) formalin-inactivated (FIV) were combining four vaccines. Mice immunized with either low or high dose PsIV FIV evaluate immunogenicity as well formulations each inactivation method. In general, PsIVs elicited equivalent higher titers neutralizing antibodies than this response was dependent. The FIVs also evaluated nonhuman primates (NHPs). Consistent what observed mice, significantly antibody serotype NHPs vaccinated compared those FIV, indicative importance epitope preservation during DENV.